香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Medcaptain Medical Technology Co., Ltd. 深圳麥科田生物醫療技術股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、聯席全球協調人、顧問或承 銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據與香港公司註冊處處長註冊的 本公司招股章程作出投資決定；招股章程的文本將於發售期內供公眾查閱。 (a) 本文件僅為向香港投資者提供有關本公司的資料，概無任何其他目的；投資者不應根據本文 件中的資料作出任何投資決定； ( ...

Core Insights - The report emphasizes that the A-share market is experiencing short-term volatility while focusing on domestic fundamentals in the medium term, with resource commodities expected to perform well [4][2] - The geopolitical situation, particularly the military actions in the Middle East, is contributing to increased uncertainty in global markets, which is likely to support gold prices in the short term [4][2] - The upcoming National People's Congress (NPC) is a key focus for domestic investors, with macroeconomic policy releases expected to influence market sentiment [4][2] Real Estate Sector: Poly Real Estate Group - Poly Real Estate Group has improved its sales ranking to 12th in the industry as of January 2026, with a sales price of 25,000 yuan per square meter [8] - The company achieved sales of 3.7 billion yuan in January 2026, a year-on-year decline of 22.9%, which is better than the average decline of 24.7% among top 100 real estate companies [8] - The company’s sales area decreased by 6.8% year-on-year, while the average sales price fell by 16.5% [8] Transportation Sector: CITIC Offshore Helicopter - CITIC Offshore Helicopter is a leading player in China's general aviation sector, operating the largest civil helicopter fleet in Asia [13] - The company has a strong operational capacity with 84 advanced helicopters and has established a significant presence in various operational areas, including offshore oil and emergency rescue [13] - The company has secured a three-year strategic cooperation agreement with CNOOC, solidifying its position in the offshore oil service market [14] Transportation Sector: China Merchants Energy Shipping - China Merchants Energy Shipping reported stable growth in 2024, with a slight decrease in revenue but a 5.59% increase in net profit [16] - The company’s fourth-quarter performance showed a significant increase in revenue and net profit, driven by a rise in container shipping volumes [16] - The outlook for 2025 suggests a tightening supply-demand balance in the oil tanker market, which may lead to improved profitability [18] Chemical Sector: Zhejiang Longsheng - Zhejiang Longsheng experienced a 6.47% decline in revenue in the first half of 2025, with a slight increase in dye business gross margin [19] - The company is focusing on cost reduction and efficiency improvements to navigate the challenges posed by industry capacity releases and tariff impacts [20] - The company maintains a strong market position in the dye and additive sectors, with ongoing developments in its real estate business [21] Chemical Sector: Yake Technology - Yake Technology reported steady revenue growth driven by LNG and electronic materials, although net profit growth lagged behind revenue due to increased exchange losses and R&D expenses [22] - The company is actively developing advanced materials for semiconductor applications, with significant revenue contributions from its electronic materials segment [23] New Energy Sector: Tianci Materials - Tianci Materials reported a significant decline in 2024 earnings, but a recovery is anticipated in Q1 2025 with a 30.80% increase in revenue [26] - The company is facing challenges in its lithium-ion battery materials business, while its daily chemical materials segment remains stable [27] Medical Sector: Mindray Medical - Mindray Medical's performance in the first half of 2025 was under pressure, but a recovery is expected in Q3 as medical equipment bidding activities improve [28] - The company is expanding its international business, with international sales accounting for about 50% of total revenue [29] - Mindray is leveraging AI technology to enhance its medical services, positioning itself for future growth opportunities [30] Food and Beverage Sector: Baba Food - Baba Food is a leading brand in Chinese-style frozen foods, with a revenue increase of 12.1% in the first three quarters of 2025 [31] - The company is optimizing its store operations and expanding its franchise model, with positive feedback on new store formats [32] - The group meal business has shown strong growth, contributing to the company's second growth curve [33] Food and Beverage Sector: Yihai International - Yihai International is expanding its market presence by developing B-end customers and exploring overseas markets [34] - The company is focusing on enhancing its supply chain capabilities and increasing its market share in Southeast Asia [34] Consumer Services Sector: China Duty Free Group - China Duty Free Group is acquiring DFS's Greater China tourism retail business to strengthen its market position in Hong Kong and Macau [35] - The company is also partnering with LVMH to enhance its brand and supply chain advantages [36] Computer Sector: Ninebot - Ninebot is focusing on innovation in short-distance transportation and service robots, with a diverse product line [37] - The company is experiencing rapid growth in overseas markets, particularly in Europe and the US, driven by strong demand for electric scooters and e-bikes [37]

Core Viewpoint - Company reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the external diagnostic industry and internal strategic investments [1] Financial Performance - The company achieved operating revenue of 332.68 million yuan, a decrease of 23.75% compared to the same period last year [1] - The net profit attributable to the parent company was 44.41 million yuan, down 65.05% year-on-year [1] Factors Affecting Performance - The primary reason for the decline in operating performance was the deep implementation of centralized procurement in the in vitro diagnostic industry, which pressured product prices and led to a decrease in main business revenue [1] - The company maintained high research and development investment to enhance core competitiveness, indicating a strategic focus on product innovation despite financial challenges [1] - There was a reduction in government subsidies and other non-recurring profit and loss items compared to the previous year, further impacting overall financial results [1]

Group 1 - The core viewpoint of the news is that RunDa Medical has experienced fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks [1][2][3] Group 2 - On February 25, RunDa Medical's stock rose by 3.79%, with a trading volume of 700 million yuan. The financing buy-in amount for the day was 67.07 million yuan, while the financing repayment was 58.99 million yuan, resulting in a net financing buy-in of 8.07 million yuan [1] - As of February 25, the total balance of margin trading for RunDa Medical was 629 million yuan, with the financing balance accounting for 6.31% of the circulating market value, indicating a high level compared to the past year [1] - The company reported a total revenue of 5.268 billion yuan for the period from January to September 2025, reflecting a year-on-year decrease of 14.70%, and a net profit attributable to shareholders of -163 million yuan, a significant decline of 422.64% [2] - RunDa Medical has distributed a total of 373 million yuan in dividends since its A-share listing, with 165 million yuan distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for RunDa Medical was 64,800, a decrease of 1.05% from the previous period, while the average circulating shares per person increased by 1.06% to 9,317 shares [2][3]

Group 1 - The core viewpoint of the news is that RunDa Medical has seen a stock price increase of 5.25%, reaching 16.85 CNY per share, with a total market capitalization of 10.172 billion CNY [1] - RunDa Medical, established on January 6, 1999, and listed on May 27, 2015, specializes in providing in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The revenue composition of RunDa Medical includes 93.50% from reagents and other consumables, 3.70% from instruments, 2.67% from software development and services, and 0.14% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has heavily invested in RunDa Medical, with the Dongcai Vision Growth Mixed Fund A (018088) increasing its holdings by 9,500 shares in the fourth quarter, making it the largest holding in the fund [2] - The Dongcai Vision Growth Mixed Fund A (018088) has a current scale of 10.8951 million CNY and has achieved a year-to-date return of 14.91%, ranking 432 out of 8,880 in its category [2] - The fund manager, Sun Chenyang, has been in position for 2 years and 307 days, with the best fund return during his tenure being 71.92% and the worst being -28.98% [3]

Core Viewpoint - RunDa Medical (603108.SH) has announced a projected net loss for 2025, estimating a loss between 5.65 billion to 4.71 billion yuan, reflecting significant operational challenges due to industry-wide price reductions and macroeconomic pressures [2][3] Financial Performance - The company's net profit for 2023 saw a year-on-year decline of 62.16%, with a further drop of 78.94% in 2024 [2] - For the first three quarters of 2025, the net profit was reported at -1.63 billion yuan, compared to a profit of 50.42 million yuan in the same period last year [2] - Overall revenue decreased by approximately 15% compared to the previous year [3] Industry Challenges - The IVD (in vitro diagnostics) sector is facing challenges due to centralized procurement policies that have led to price reductions, impacting revenue and profit margins [3][7] - The implementation of centralized procurement has resulted in lower product prices and delayed payment cycles from public hospitals, exacerbating financial pressures on the company [3][4] Subsidiary Performance - Some subsidiaries of RunDa Medical have not met profitability expectations, leading to an anticipated goodwill impairment provision of 180 million to 220 million yuan [4] - The company has noted that accounts receivable collection periods have lengthened due to financial pressures on hospitals, although the risk of bad debts remains low [4][5] Business Segments - RunDa Medical's business is divided into three main segments: commercial, industrial, and emerging AI medical services, all of which are experiencing varying degrees of pressure [6] - The commercial segment, which is the main revenue driver, reported a revenue decline of 8.34% in 2024, with further declines in specific areas such as centralized testing services and third-party laboratory services [6] Future Outlook - The company is focusing on AI medical and digital business as future growth areas, with the medical information business showing a 40.73% revenue increase in the first half of 2025 [8] - However, the new business segments are not expected to compensate for the decline in traditional business in the short term [8][9] - RunDa Medical plans to leverage its technological expertise in smart healthcare to enhance its service offerings and operational efficiency [9][10]

Core Viewpoint - RunDa Medical has announced a projected net loss for the fiscal year 2025, estimating a loss between 565 million yuan and 471 million yuan, a significant decline compared to a profit of 55.28 million yuan in the same period last year [1] Group 1: Financial Performance - The company's revenue is expected to decrease by approximately 15% compared to the same period last year due to changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry [1] - The gross profit margin has also experienced a decline, contributing to the overall expected loss [1] Group 2: Cost Management and Operational Challenges - In response to external environmental changes, the company has implemented various cost control and expense management measures to enhance operational efficiency [1] - Fixed costs such as depreciation, amortization, and financing expenses have not decreased in proportion to the revenue decline, impacting overall profitability [1] Group 3: Impairment and Receivables - The company anticipates recognizing goodwill impairment provisions between 180 million yuan and 220 million yuan based on the actual operating conditions of certain subsidiaries, with the final amount subject to audit and evaluation [1] - There has been an extension in the collection period for accounts receivable, leading the company to make credit impairment provisions for related receivables [1]

1. Report Title and Date - The report is titled "Convertible Bond Industry Chain Big Map - February 2026" and was issued on February 3, 2026 [1] 2. Analysts and Contact Information - Analysts are Yang Yewei and Wang Sufang, with their respective license numbers S0680520050001 and S0680524060002, and email addresses yangyewei@gszq.com and wangsufang@gszq.com [2][3] 3. Hot Topics and Related Convertible Bonds 3.1 "Brain - Machine Interface" - Convertible bonds related to this topic include Lepu Convertible Bond 2, Yiwei Convertible Bond, Kelan Convertible Bond, Jiahe Convertible Bond, and Seli Convertible Bond, with details such as their prices, premiums, balances, and associations with the brain - machine interface provided [5] 3.2 "Commercial Spaceflight" (Part 1) - Convertible bonds include Qifan Convertible Bond, Lion Convertible Bond, Ruike Convertible Bond, etc., with information about their industries, prices, and associations with the commercial spaceflight field [7] 3.3 "Commercial Spaceflight" (Part 2) - Convertible bonds like Tian23 Convertible Bond, Guoli Convertible Bond, and Mengsheng Convertible Bond are related, and their details are presented [10] 4. Industry Chains and Related Convertible Bonds 4.1 Power, Electrical Equipment Industry Chain - It includes segments such as power generation, power equipment, and energy storage, with a list of related convertible bonds like Jieneng Convertible Bond, Jinke Convertible Bond, etc. The top 10 convertible bonds by trading volume in January are also provided, including details like trading volume, price, and premiums [13][15] 4.2 Mining, Non - ferrous Metals, and Chemical Industry Chain - Covers various segments such as basic chemicals, chemical fibers, and coal. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are presented, including their trading volumes, prices, and other indicators [17][19] 4.3 Machinery, Transportation, and Automobile Industry Chain - Comprises machinery, automobile parts, and logistics segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [22][24] 4.4 Electronics Industry Chain - Includes semiconductor materials, electronic chemicals, etc. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are provided, with details like trading volume, price, and premiums [27][32] 4.5 Military and TMT Industry Chain - Involves communication equipment, military, computer, and media segments. Related convertible bonds are listed, and information about some convertible bonds' trading volume, price, and other aspects in January is presented [35][38] 4.6 Real Estate Industry Chain - Covers building materials, construction engineering, and household appliances segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [41][46] 4.7 Financial Industry Chain - Divided into non - banking finance and banking segments. All related convertible bonds are listed, and information about their trading volume, price, and other indicators in January is provided [49][52] 4.8 Light Industry and Downstream Consumption Industry Chain - Encompasses papermaking, agriculture, forestry, animal husbandry, and fishery, and other segments. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are presented, including trading volumes, prices, and premiums [55][57] 4.9 Pharmaceutical and Biological Industry Chain - Includes pharmaceutical product production, medical devices, and pharmaceutical circulation. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are provided, with details like trading volume, price, and premiums [60][64] 4.10 Environmental Protection Industry Chain - Covers environmental monitoring, comprehensive treatment, and waste treatment. Related convertible bonds are listed, and the top 10 convertible bonds by January trading volume are shown, including trading volumes, prices, and premiums [67][69]

Group 1 - The core viewpoint of the news is that RunDa Medical has seen a stock price increase of 5.12%, reaching 16.22 CNY per share, with a trading volume of 284 million CNY and a turnover rate of 2.97%, resulting in a total market capitalization of 9.792 billion CNY [1] - RunDa Medical, established on January 6, 1999, and listed on May 27, 2015, is located in Shanghai and primarily provides in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The company's main revenue composition includes reagents and other consumables at 93.50%, instruments at 3.70%, software development and services at 2.67%, and other (supplementary) at 0.14% [1] Group 2 - From the perspective of RunDa Medical's top ten circulating shareholders, Southern Fund's Southern CSI 1000 ETF (512100) reduced its holdings by 48,700 shares in the third quarter, now holding 4.4119 million shares, which accounts for 0.73% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY, and has achieved a year-to-date return of 4.98%, ranking 1606 out of 5562 in its category [2] - The fund manager, Cui Lei, has a cumulative tenure of 7 years and 90 days, with the fund's total asset scale at 137.02 billion CNY, achieving the best return of 279.97% and the worst return of -15.93% during the tenure [2]

Core Viewpoint - RunDa Medical (603108.SH) is expected to report a net loss attributable to shareholders of the parent company ranging from -565 million to -471 million yuan for the fiscal year 2025, indicating a decline compared to the previous year [1] Group 1: Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be between -588 million and -490 million yuan for 2025 [1] - The company's revenue is anticipated to decrease by approximately 15% compared to the same period last year due to changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry [1] Group 2: Operational Challenges - The decline in revenue and gross margin is attributed to the impact of external environmental changes and pricing pressures on products [1] - Despite efforts to enhance management efficiency and implement cost control measures, fixed costs such as depreciation and financing expenses have not decreased in proportion to the revenue decline [1] Group 3: Impairment and Credit Risks - The company expects to recognize goodwill impairment provisions ranging from 180 million to 220 million yuan for certain subsidiaries due to their underperformance [1] - There has been an extension in the collection period for accounts receivable, leading the company to make credit impairment provisions for related accounts [1]